Cargando…
Impact of JAK2 V617F Mutation on Hemogram Variation in Patients with Non-Reactive Elevated Platelet Counts
BACKGROUND: Non-reactive platelet counts elevation occurs mainly in myeloproliferative disorders (MPDs), which have been reported to be closely associated with JAK2 V617F mutation. Complete blood cell count (CBC) is essential in diagnosis of MPDs, however, the impact of JAK2 V617F mutation on the pa...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3585181/ https://www.ncbi.nlm.nih.gov/pubmed/23469088 http://dx.doi.org/10.1371/journal.pone.0057856 |
_version_ | 1782261114364493824 |
---|---|
author | Zhou, Juan Ye, Yuanxin Zeng, Shugen Zhou, Yi Mao, Zhigang Song, Xingbo Ying, Binwu Lu, Xiaojun Jiang, Hong Wang, Lanlan |
author_facet | Zhou, Juan Ye, Yuanxin Zeng, Shugen Zhou, Yi Mao, Zhigang Song, Xingbo Ying, Binwu Lu, Xiaojun Jiang, Hong Wang, Lanlan |
author_sort | Zhou, Juan |
collection | PubMed |
description | BACKGROUND: Non-reactive platelet counts elevation occurs mainly in myeloproliferative disorders (MPDs), which have been reported to be closely associated with JAK2 V617F mutation. Complete blood cell count (CBC) is essential in diagnosis of MPDs, however, the impact of JAK2 V617F mutation on the patients’ hemogram variation remains not clear. METHODS: JAK2 V617F mutation was detected by allele specific real-time quantitative fluorescence PCR (AS-qPCR). RESULTS: Of the 402 non-reactive platelet elevating patients, JAK2 V617F mutation was detected in 222 (55.2%) patients. RBC counts, WBC counts, platelet-large contrast ratio (P-LCR), platelet distribution width (PDW) and mean platelet volume (MPV) were much higher in JAK2 V617F mutated patients, except platelet counts. In addition, when the patients were classified into subgroups by blood cell counts, it was found that JAK2 V617F mutation rate increased progressively with the increase of RBC counts and WBC counts, other than platelet counts. Furthermore, trilineage hyperplasia group showed highest JAK2 V617F mutation rate (93.26%), followed by the bilineage hyperplasia groups. Lastly, JAK2 V617F mutant allele burden was found much higher in polycythemia vera (PV) patients [median(P(25)–P(75)): 45.02%(35.12%–54.22%)] than in essential thrombocythemia (ET) patients [median(P(25)–P(75)): 28.23%(17.77%–41.66%)], and that it increased with WBC counts (r = 0.393, p = 0.000) and RBC counts(r = 0.215, p = 0.001), other than platelet counts (r = −0.051, p = 0.452). Further analysis revealed that in ET patients, JAK2 V617F mutant allele burden correlated with WBC counts and platelet counts positively, other than RBC counts, while in PV patients, it correlated with WBC counts and RBC counts positively, but not platelet counts. CONCLUSIONS: JAK2 V617F mutation occurs frequently in patients with non-reactive elevated platelet counts. The presence of JAK2 V617F mutation has great impact on hemogram variation, including RBC counts, WBC counts, platelet parameters and lineage hyperplasia, but not on platelet counts. Besides, JAK2 V617F mutant allele burden affects the blood cell proliferation pattern. |
format | Online Article Text |
id | pubmed-3585181 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-35851812013-03-06 Impact of JAK2 V617F Mutation on Hemogram Variation in Patients with Non-Reactive Elevated Platelet Counts Zhou, Juan Ye, Yuanxin Zeng, Shugen Zhou, Yi Mao, Zhigang Song, Xingbo Ying, Binwu Lu, Xiaojun Jiang, Hong Wang, Lanlan PLoS One Research Article BACKGROUND: Non-reactive platelet counts elevation occurs mainly in myeloproliferative disorders (MPDs), which have been reported to be closely associated with JAK2 V617F mutation. Complete blood cell count (CBC) is essential in diagnosis of MPDs, however, the impact of JAK2 V617F mutation on the patients’ hemogram variation remains not clear. METHODS: JAK2 V617F mutation was detected by allele specific real-time quantitative fluorescence PCR (AS-qPCR). RESULTS: Of the 402 non-reactive platelet elevating patients, JAK2 V617F mutation was detected in 222 (55.2%) patients. RBC counts, WBC counts, platelet-large contrast ratio (P-LCR), platelet distribution width (PDW) and mean platelet volume (MPV) were much higher in JAK2 V617F mutated patients, except platelet counts. In addition, when the patients were classified into subgroups by blood cell counts, it was found that JAK2 V617F mutation rate increased progressively with the increase of RBC counts and WBC counts, other than platelet counts. Furthermore, trilineage hyperplasia group showed highest JAK2 V617F mutation rate (93.26%), followed by the bilineage hyperplasia groups. Lastly, JAK2 V617F mutant allele burden was found much higher in polycythemia vera (PV) patients [median(P(25)–P(75)): 45.02%(35.12%–54.22%)] than in essential thrombocythemia (ET) patients [median(P(25)–P(75)): 28.23%(17.77%–41.66%)], and that it increased with WBC counts (r = 0.393, p = 0.000) and RBC counts(r = 0.215, p = 0.001), other than platelet counts (r = −0.051, p = 0.452). Further analysis revealed that in ET patients, JAK2 V617F mutant allele burden correlated with WBC counts and platelet counts positively, other than RBC counts, while in PV patients, it correlated with WBC counts and RBC counts positively, but not platelet counts. CONCLUSIONS: JAK2 V617F mutation occurs frequently in patients with non-reactive elevated platelet counts. The presence of JAK2 V617F mutation has great impact on hemogram variation, including RBC counts, WBC counts, platelet parameters and lineage hyperplasia, but not on platelet counts. Besides, JAK2 V617F mutant allele burden affects the blood cell proliferation pattern. Public Library of Science 2013-02-28 /pmc/articles/PMC3585181/ /pubmed/23469088 http://dx.doi.org/10.1371/journal.pone.0057856 Text en © 2013 Zhou et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Zhou, Juan Ye, Yuanxin Zeng, Shugen Zhou, Yi Mao, Zhigang Song, Xingbo Ying, Binwu Lu, Xiaojun Jiang, Hong Wang, Lanlan Impact of JAK2 V617F Mutation on Hemogram Variation in Patients with Non-Reactive Elevated Platelet Counts |
title | Impact of JAK2 V617F Mutation on Hemogram Variation in Patients with Non-Reactive Elevated Platelet Counts |
title_full | Impact of JAK2 V617F Mutation on Hemogram Variation in Patients with Non-Reactive Elevated Platelet Counts |
title_fullStr | Impact of JAK2 V617F Mutation on Hemogram Variation in Patients with Non-Reactive Elevated Platelet Counts |
title_full_unstemmed | Impact of JAK2 V617F Mutation on Hemogram Variation in Patients with Non-Reactive Elevated Platelet Counts |
title_short | Impact of JAK2 V617F Mutation on Hemogram Variation in Patients with Non-Reactive Elevated Platelet Counts |
title_sort | impact of jak2 v617f mutation on hemogram variation in patients with non-reactive elevated platelet counts |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3585181/ https://www.ncbi.nlm.nih.gov/pubmed/23469088 http://dx.doi.org/10.1371/journal.pone.0057856 |
work_keys_str_mv | AT zhoujuan impactofjak2v617fmutationonhemogramvariationinpatientswithnonreactiveelevatedplateletcounts AT yeyuanxin impactofjak2v617fmutationonhemogramvariationinpatientswithnonreactiveelevatedplateletcounts AT zengshugen impactofjak2v617fmutationonhemogramvariationinpatientswithnonreactiveelevatedplateletcounts AT zhouyi impactofjak2v617fmutationonhemogramvariationinpatientswithnonreactiveelevatedplateletcounts AT maozhigang impactofjak2v617fmutationonhemogramvariationinpatientswithnonreactiveelevatedplateletcounts AT songxingbo impactofjak2v617fmutationonhemogramvariationinpatientswithnonreactiveelevatedplateletcounts AT yingbinwu impactofjak2v617fmutationonhemogramvariationinpatientswithnonreactiveelevatedplateletcounts AT luxiaojun impactofjak2v617fmutationonhemogramvariationinpatientswithnonreactiveelevatedplateletcounts AT jianghong impactofjak2v617fmutationonhemogramvariationinpatientswithnonreactiveelevatedplateletcounts AT wanglanlan impactofjak2v617fmutationonhemogramvariationinpatientswithnonreactiveelevatedplateletcounts |